University of Dundee

Latest News for 09/2020

August 2020

  • Dr Susan Wyllie
    27 Aug 2020

    Scientists at the Wellcome Centre for Anti-Infectives Research (WCAIR) at the University of Dundee have been awarded £4.9million in follow-on funding from the Wellcome Trust, boosting their efforts to understand more about potential drugs that could be used to treat neglected tropical diseases (NTDs) and other parasitic diseases.

April 2020

  • DDD10749 - Malaria Compound
    28 Apr 2020

    Back in October 2013 Medicines for Malaria Venture (MMV) selected a compound designed and developed at the Drug Discovery Unit (DDU), University of Dundee to enter preclinical development. In June 2015, the discovery, properties and mode of action of the compound DDD107498 were published in the journal Nature.

March 2020

  • Professor Ian Gilbert and Professor Miratul Muqit
    03 Mar 2020

    Two Life Sciences academics who are helping transform lives with their work on major diseases including Parkinson’s and neglected tropical diseases such as malaria have been elected Fellows of the Royal Society of Edinburgh (RSE). The RSE is Scotland’s national academy, focused on delivering its mission of `knowledge made useful’. Fellows are elected in recognition of their impact in improving the world around them.

July 2019

  • left to right, Professor Kevin Grant, Dr Beatriz Baragaña and Professor Ian Gilbert, all of the Drug Discovery Unit
    11 Jul 2019

    Researchers from the Drug Discovery Unit have been awarded the “Project of the Year 2018” from Medicines for Malaria Venture (MMV) for their discovery work on potential new drugs for malaria. The annual award goes to the scientific partners involved in that year’s most exciting project from the MMV portfolio. MMV is the world’s leading product development partnership (PDP) for discovering and developing new effective and affordable medicines to treat malaria.

February 2019

  • 12 Feb 2019

    Researchers in the Wellcome Centre for Anti-Infectives Research (WCAIR) have been awarded £700,000 to investigate whether bacteria and other natural products found in the Amazon hold the key to developing new drugs for neglected tropical diseases. The team led by Professor Kevin Read will work with colleagues in Brazil to identify novel drug targets and develop new therapies for visceral leishmaniasis and Chagas’ disease.

July 2018

June 2017

  • 14 Jun 2017

    Ten partnership building projects, including two from the School, have been awarded internal Pump-Priming Funding from the University’s SFC GCRF funding allocation. The aim of the competition, coordinated by Research & Innovation Services (RIS), is to enhance our ability to respond to funding opportunities under the Global Challenges Research Fund (GCRF).

March 2017

  • 27 Mar 2017

    Antimicrobial resistance is one of the greatest threats to global human and animal health – the O’Neill Report published last year stated that, unless we take urgent action, it will be directly responsible for over 10 million deaths by 2050, more than deaths from cancer or deaths from diabetes, road traffic accidents and cholera combined. A crucial part of the solution is to find new antibiotics to tackle bacterial infections and replace existing treatments which have become ineffective, often through over

January 2017

  • 17 Jan 2017

    The School hosted the 45th Scottish Regional Meeting of the Royal Society of Chemistry (RSC) Organic Division on 11th January. The conference is traditionally called the "Perkin Meeting”, and it brings together all the organic chemists in Scotland for a 1 day meeting every year.  It includes the Organic Chemistry Departments of Edinburgh, Glasgow, Strathclyde, Herriot-Watt, St Andrews, Aberdeen and Dundee.

June 2015

  • 30 Jun 2015

    The Drug Discovery Unit at the University of Dundee has been awarded “Project of the Year, 2014” by the not-for-profit organisation, Medicines for Malaria Venture for their work on the new potential anti-malaria compound “DDD107498 – The Compound with Muscle”.  The discovery of the compound was recently published in the journal Nature and has been selected as a preclinical candidate by MMV and recently partnered with the pharmaceutical company Merck Serono. 

Pages